Perhaps the biggest trend health information technology today is the movement away from traditional picture archiving and communications systems (PACS) and cardiovascular information systems (CVIS) to enterprise imaging and data management systems. This migration is important, because it will fundamentally change how clinicians have been accessing images and patient information for the past 20 years. 
 

IBA (Ion Beam Applications S.A.), a global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, is proud to support the Union for International Cancer Control (UICC) by participating in World Cancer Day on February 4, 2015.  IBA’s mission to “Protect, Enhance and Save Lives” reflects the understanding that lives are impacted by the efforts of all of IBA’s employees in developing the solutions, education and services for fighting cancer. World Cancer Day offers the perfect platform to take a moment and focus on this cause from a very personal aspect.

In 1934, a Senate committee opened hearings its chairman said would show that America’s involvement in WWI was “not a matter of national honor and national defense, but a matter of profit for the few.” Ninety-three hearings and 200 witnesses, however, did little to support that claim. Rather the hearings drew increased attention to arms manufacturers as “merchants of death” and inspired Congress to pass three neutrality acts that signaled “profound American opposition to overseas involvement” in the years preceding America’s entry into WWII.1

A new Mayo Clinic study finds that not all women with lymph node-positive breast cancer treated with chemotherapy before surgery need to have all of their underarm nodes taken out. Ultrasound is a useful tool for judging before breast cancer surgery whether chemotherapy eliminated cancer from the underarm lymph nodes, the researchers found. The findings are published in the Journal of Clinical Oncology.

Radiologists at the prestigious Dana-Farber Cancer Institute (Boston, Mass.) are using Carestream’s lesion management module with Carestream Vue PACS to capture information about tumors and how they respond to treatment.

February 4, 2015 — Lantheus Medical Imaging Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) allowing Jubilant HollisterStier (JHS) to be a new manufacturer for its proprietary brain perfusion imaging agent Neurolite.


The Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology (ONC) released Connecting Health and Care for the Nation: A Shared Nationwide Interoperability Roadmap Version 1.0. 


Intelerad Medical Systems has been awarded a five-year, Schedule 70 contract with the U.S. General Services Administration (GSA).

Subscribe Now